Adcentrx Therapeutics is a clinical-stage biotechnology company headquartered in San Diego, California, developing next-generation antibody-drug conjugates (ADCs) and protein conjugate therapeutics for cancer and other life-threatening diseases. Its proprietary i-Conjugation technology platform pairs stable conjugation chemistry and protease-cleavable linkers with novel small-molecule payloads; the clinical pipeline includes ADRX-0706 (Nectin-4) and ADRX-0405 (STEAP1). The company was surfaced via the API Evangelist harvest backlog (source: secondary-market). It publishes a corporate and investor-relations website only — no developer program, API, SDK, or machine-readable specification of any kind was found.
Adcentrx Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Oncology.
Adcentrx Therapeutics’ developer surface includes engineering blog, support, and 7 more developer resources.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
aid: adcentrxtherapeutics
name: Adcentrx Therapeutics
description: 'Adcentrx Therapeutics is a clinical-stage biotechnology company headquartered in San Diego, California, developing
next-generation antibody-drug conjugates (ADCs) and protein conjugate therapeutics for cancer and other life-threatening
diseases. Its proprietary i-Conjugation technology platform pairs stable conjugation chemistry and protease-cleavable linkers
with novel small-molecule payloads; the clinical pipeline includes ADRX-0706 (Nectin-4) and ADRX-0405 (STEAP1). The company
was surfaced via the API Evangelist harvest backlog (source: secondary-market). It publishes a corporate and investor-relations
website only — no developer program, API, SDK, or machine-readable specification of any kind was found.'
image: https://www.adcentrx.com/wp-content/uploads/2021/11/Adcentrx-logo.png
url: https://raw.githubusercontent.com/api-evangelist/adcentrxtherapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-09-07'
modified: '2026-09-07'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Oncology
- Healthcare
- Clinical Stage
- Antibody-Drug Conjugates
tags_raw:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Oncology
- Healthcare
- Clinical Stage
- Antibody Drug Conjugates
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: DomainSecurity
url: security/adcentrxtherapeutics-domain-security.yml
- type: Website
url: https://www.adcentrx.com/
- type: About
url: https://www.adcentrx.com/about/
- type: Blog
url: https://www.adcentrx.com/news/
- type: BlogRSS
url: https://www.adcentrx.com/feed/
- type: Support
url: https://www.adcentrx.com/contact/
- type: TermsOfService
url: https://www.adcentrx.com/terms-of-use/
- type: PrivacyPolicy
url: https://www.adcentrx.com/privacy-policy/
- type: LinkedIn
url: https://www.linkedin.com/company/adcentrx-therapeutics
x-enrichment:
date: '2026-09-07'
status: minimal
artifacts_added: 2
pass: local-v3
x-coverage:
state: none
reason: not-a-software-company
detail: Adcentrx Therapeutics is a clinical-stage oncology biotech developing antibody-drug conjugates (ADRX-0706, ADRX-0405);
its only web property is a SiteGround-hosted WordPress corporate/investor site whose entire path space answers HTTP 202
with an sg-captcha robot challenge, and no api., docs., developer. or portal. host exists in DNS - the site nav, read
from an Internet Archive snapshot, has no developer section.
evidence:
- url: https://www.adcentrx.com/
status: 202
- url: https://www.adcentrx.com/.well-known/api-catalog
status: 202
- url: https://www.adcentrx.com/openapi.json
status: 202
- url: http://web.archive.org/web/20260810050011/https://www.adcentrx.com/
status: 200
checked: '2026-09-07'
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.
Kin Score
How this is scored →